- Home
- CGEN vs BCV Comparison
CGEN vs BCV Comparison
Compare CGEN & BCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- BCV
- Stock Information
- Founded
- CGEN 1993
- BCV 1971
- Country
- CGEN Israel
- BCV United States
- Employees
- CGEN N/A
- BCV N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- BCV Finance/Investors Services
- Sector
- CGEN Health Care
- BCV Finance
- Exchange
- CGEN Nasdaq
- BCV Nasdaq
- Market Cap
- CGEN 125.3M
- BCV 138.9M
- IPO Year
- CGEN 2000
- BCV N/A
- Fundamental
- Price
- CGEN $1.65
- BCV $21.91
- Analyst Decision
- CGEN
- BCV
- Analyst Count
- CGEN 0
- BCV 0
- Target Price
- CGEN N/A
- BCV N/A
- AVG Volume (30 Days)
- CGEN 324.9K
- BCV 26.3K
- Earning Date
- CGEN 11-10-2025
- BCV 01-01-0001
- Dividend Yield
- CGEN N/A
- BCV 8.13%
- EPS Growth
- CGEN N/A
- BCV N/A
- EPS
- CGEN N/A
- BCV N/A
- Revenue
- CGEN $6,903,000.00
- BCV N/A
- Revenue This Year
- CGEN N/A
- BCV N/A
- Revenue Next Year
- CGEN $208.08
- BCV N/A
- P/E Ratio
- CGEN N/A
- BCV N/A
- Revenue Growth
- CGEN N/A
- BCV N/A
- 52 Week Low
- CGEN $1.13
- BCV $14.09
- 52 Week High
- CGEN $2.66
- BCV $18.11
- Technical
- Relative Strength Index (RSI)
- CGEN 46.42
- BCV 33.67
- Support Level
- CGEN $1.54
- BCV $22.85
- Resistance Level
- CGEN $1.79
- BCV $23.67
- Average True Range (ATR)
- CGEN 0.11
- BCV 0.34
- MACD
- CGEN -0.01
- BCV -0.24
- Stochastic Oscillator
- CGEN 34.62
- BCV 0.00
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.